Federal Register / Vol. 77, No. 46 / Thursday, March 8, 2012 / Notices 14017 

Keith A. Tucker, 

Office of the Secretary, Paperwork Reduction 

Act Reports Clearance Officer. 

[FR Doc. 2012–5666 Filed 3–7–12; 8:45 am] 

BILLING CODE 4150–05–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

World Trade Center Health Program 

Scientific/Technical Advisory 

Committee (WTCHP STAC or Advisory 

Committee), National Institute for 

Occupational Safety and Health 

(NIOSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned committee: 

Time and Date: 1 p.m.–5 p.m., March 28, 

2012. 

Place: This meeting is available via 

telephone and Web Conference. Audio will 

be available by telephone and visuals will be 

available by Web Conference. The USA tollfree, dial-in number is 1–800–593–0693. To 

be connected to the meeting, you will need 

to provide the following participant code to 

the operator: 4447238. To obtain further 

instructions on how to access the meeting 

online through Web Conference, see the 

instructions at the Committee’s Web site: 

http://www.cdc.gov/NIOSH/topics/wtc/stac/ 

meetings/. 

Public Comment Times and Date: 1:10 

p.m.–1:55 p.m., March 28, 2012. 

Please note that the public comment period 

ends at the time indicated above or following 

the last call for comments, whichever is 

earlier. Members of the public who want to 

comment must sign up by providing their 

name by mail, facsimile, email, or telephone, 

as given below. Each commenter will be 

provided up to five minutes for comment. A 

limited number of time slots are available 

and will be assigned on a first come-first 

served basis. Written comments will also be 

accepted from those unable to attend the 

public session. 

Status: Open to the public, limited only by 

the number of telephone lines. The 

conference line will accommodate up to 300 

callers; therefore it is suggested that those 

interested in calling in to listen to the 

committee meeting share a line when 

possible. 

Background: The Advisory Committee was 

established by Public Law 111–347 (The 

James Zadroga 9/11 Health and 

Compensation Act of 2010, Title XXXIII of 

the Public Health Service Act), enacted on 

January 2, 2011 and codified at 42 U.S.C. 

300mm–300mm–61. 

Purpose: The purpose of the Advisory 

Committee is to review scientific and 

medical evidence and to make 

recommendations to the World Trade Center 

(WTC) Program Administrator regarding 

additional WTC Health Program eligibility 

criteria and potential additions to the list of 

covered WTC-related health conditions. Title 

XXXIII of the Public Health Service Act 

established within the Department of Health 

and Human Services (HHS), the World Trade 

Center (WTC) Health Program, to be 

administered by the WTC Program 

Administrator. The WTC Health Program 

provides: (1) Medical monitoring and 

treatment benefits to eligible emergency 

responders and recovery and cleanup 

workers (including those who are Federal 

employees) who responded to the September 

11, 2001, terrorist attacks, and (2) initial 

health evaluation, monitoring, and treatment 

benefits to residents and other building 

occupants and area workers in New York 

City, who were directly impacted and 

adversely affected by such attacks 

(‘‘survivors’’). Certain specific activities of 

the WTC Program Administrator are reserved 

to the Secretary, HHS, to delegate at her 

discretion; other WTC Program 

Administrator duties not explicitly reserved 

to the Secretary, HHS, are assigned to the 

Director, NIOSH. The administration of the 

Advisory Committee established under 

Section 300mm–1(a) is left to the Director of 

NIOSH in his role as WTC Program 

Administrator. CDC and NIOSH provide 

funding, staffing, and administrative support 

services for the Advisory Committee. The 

charter was issued on May 12, 2011, and will 

expire on May 12, 2013. 

Matters To Be Discussed: The agenda for 

the Advisory Committee meeting includes 

the petition to add cancer, or types of cancer, 

to the list of covered WTC-related health 

conditions. The agenda is subject to change 

as priorities dictate. In the event an 

individual cannot attend, written comments 

may be submitted. The comments should be 

limited to two pages and submitted to the 

contact person below by March 23, 2012. 

Efforts will be made to provide the two-page 

written comments received by the deadline 

below to the committee members before the 

meeting. Comments in excess of two pages 

will be made publicly available at the NIOSH 

docket (http://www.cdc.gov/niosh/docket/ 

archive/docket248.html). 

Public Comment Sign-up and Submissions 

to the Docket: To sign up to provide public 

comments or to submit comments to the 

docket, send information to the NIOSH 

Docket Office by one of the following means: 

Mail: NIOSH Docket Office, Robert A. Taft 

Laboratories, MS–C–34, 4676 Columbia 

Parkway, Cincinnati, Ohio 45226. 

Facsimile: (513) 533–8285. 

Email: nioshdocket@cdc.gov. 

Telephone: (513) 533–8611. 

Submissions to the docket should reference 

docket #248. 

Policy on Redaction of Committee Meeting 

Transcripts (Public Comment): Transcripts 

will be prepared and posted to NIOSH 

Docket 248 within 60 days after the meeting. 

If a person making a comment gives his or 

her name, no attempt will be made to redact 

that name. NIOSH will take reasonable steps 

to ensure that individuals making public 

comments are aware of the fact that their 

comments (including their name, if provided) 

will appear in a transcript of the meeting 

posted on a public Web site. Such reasonable 

steps include a statement read at the start of 

the meeting stating that transcripts will be 

posted and names of speakers will not be 

redacted. If individuals in making a 

statement reveal personal information (e.g., 

medical information) about themselves, that 

information will not usually be redacted. The 

CDC Freedom of Information Act coordinator 

will, however, review such revelations in 

accordance with the Freedom of Information 

Act and if deemed appropriate, will redact 

such information. Disclosures of information 

concerning third party medical information 

will be redacted. 

Contact Person for More Information: Paul 

J. Middendorf, Ph.D., Designated Federal 

Officer, NIOSH, CDC, 4676 Columbia 

Parkway Mail Stop R–45, Cincinnati, Ohio 

45226, telephone 1 (888) 982–4748; email: 

wtc-stac@cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register Notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Dated: March 21, 2012. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2012–5624 Filed 3–7–12; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: Head Start Grants 

Administration. 

OMB No.: 0980–0243. 

Description: 45 CFR part 1301 

contains provisions applicable to the 

program administration and grants 

administration under the Head Start 

Act, as amended. These provisions 

specify the requirements for grantee 

agencies for insurance and bonding, the 

submission of audits, matching of 

federal funds, accounting systems and 

certifications and other provisions 

applicable to personnel managements. 

Respondents: Head Start and Early 

Head Start grantees 


wreier-aviles on DSK5TPTVN1PROD with NOTICES
14018 Federal Register / Vol. 77, No. 46 / Thursday, March 8, 2012 / Notices 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total 

burden hours 

Information Collections .................................................................................... 2,700 1 2 5,400 

Estimated Total Annual Burden 

Hours: 5,400. 

Additional Information 

Copies of the proposed collection may 

be obtained by writing to the 

Administration for Children and 

Families, Office of Planning, Research 

and Evaluation, 370 L’Enfant 

Promenade, SW., Washington, DC 

20447, Attn: ACF Reports Clearance 

Officer. All requests should be 

identified by the title of the information 

collection. Email address: 

infocollection@acf.hhs.gov. 

OMB Comment 

OMB is required to make a decision 

concerning the collection of information 

between 30 and 60 days after 

publication of this document in the 

Federal Register. Therefore, a comment 

is best assured of having its full effect 

if OMB receives it within 30 days of 

publication. Written comments and 

recommendations for the proposed 

information collection should be sent 

directly to the following: Office of 

Management and Budget, Paperwork 

Reduction Project. Fax: 202–395–7285, 

Email: OIRA_SUBMISSION@OMB.EOP.

GOV. Attn: Desk Officer for the 

Administration for Children and 

Families. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2012–5600 Filed 3–7–12; 8:45 am] 

BILLING CODE 4184–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2011–N–0553] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Potential Tobacco 

Product Violations Reporting Form 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995 

(the PRA). 

DATES: Fax written comments on the 

collection of information by April 9, 

2012. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be faxed to the Office of 

Information and Regulatory Affairs, 

OMB, Attn: FDA Desk Officer, FAX: 

202–395–7285, or emailed to oira_

submission@omb.eop.gov. All 

comments should be identified with the 

OMB control number 0910–NEW and 

title ‘‘Potential Tobacco Product 

Violations Reporting Form.’’ Also 

include the FDA docket number found 

in brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

Daniel Gittleson, Office of Information 

Management, Food and Drug 

Administration, 1350 Piccard Dr., PI50– 

400B, Rockville, MD 20850, 301–796– 

5156, daniel.gittleson@fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Potential Tobacco Product Violations 

Reporting Form—(OMB Control 

Number 0910–NEW) 

On June 22, 2009, the President 

signed the Family Smoking Prevention 

and Tobacco Control Act (the Tobacco 

Control Act) (Pub. L. 111–31) into law. 

The Tobacco Control Act amended the 

Federal Food, Drug, and Cosmetic Act 

(the FD&C Act) (21 U.S.C. 321 et. seq.) 

by adding a new chapter granting FDA 

important new authority to regulate the 

manufacture, marketing, and 

distribution of tobacco products to 

protect the public health generally and 

to reduce tobacco use by minors. 

FDA is requesting OMB approval for 

a new collection of information to 

accept consumer and other stakeholder 

feedback and notification of potential 

tobacco violations of the FD&C Act, as 

amended by the Tobacco Control Act. 

As part of its enforcement strategy, 

FDA created a Tobacco Call Center 

(with a toll-free number: 1–877–CTP– 

1373) to accept information from the 

public about violations of the Tobacco 

Control Act. Callers are able to report 

potential violations of the Tobacco 

Control Act, and FDA may conduct 

targeted followup investigation based on 

information received. When callers 

report a violation, the caller will be 

asked to provide as much information as 

they can recall, including: The date the 

potential violation happened, the 

product type (e.g., cigarette, smokeless, 

roll-your-own, etc.), tobacco brand, type 

of potentially violative promotional 

materials, potential violation type, who 

potentially violated, and the name, 

address, phone number, and email 

address of the potential violator. The 

caller will also be asked to list the 

potential violator’s Web site (if 

available), describe the potential 

violation, and provide any additional 

files or information pertinent to the 

potential violation. FDA has developed 

a form that will be used to solicit this 

information from the caller (Form FDA 

3779, Potential Tobacco Product 

Violations Reporting), which is 

expected to eventually replace current 

Form FDA 3734 for Cigarette Flavor Ban 

Violations. This new form will be 

posted on FDA’s Web site, and 

information may be submitted by filling 

out the form online (or the public can 

request a copy of Form FDA 3779 by 

contacting the Center for Tobacco 

Products (CTP)). In addition, FDA has 

developed a smartphone application for 

use with mobile devices (i.e., iPhones, 

Android) to allow consumers to report 

potential violations to FDA via their 

smartphone. Others may simply choose 

to send a letter to FDA with their 

information. In summary, the public 

and interested stakeholders will be able 

to report information regarding possible 

violations of the Tobacco Control Act 

through the following methods: Calling 

the Tobacco Call Center using CTP’s 

toll-free number, using a fill-able form 

found on FDA’s Web site, using FDA’s 

tobacco violation reporting smartphone 

application, and sending a letter to 

FDA’s Center for Tobacco Products. 

In the Federal Register of August 22, 

2011 (76 FR 52333), FDA published a 

60-day notice requesting public 

comment on this proposed collection of 

information. FDA received 24 comment 

submissions, which included over 60 


wreier-aviles on DSK5TPTVN1PROD with NOTICES